In vivo synthesis of tumor necrosis factor-α in healthy humans after live yellow fever vaccination

Journal of Infectious Diseases

Volumn 177, Issue 3, 1998, Pages 774-778

  Hacker, U T ^b   Jelinek, T ^b   Erhardt, S ^b   Eigler, A ^b   Hartmann, G ^b   Nothdurft, H D ^b   Endres, S ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A VACCINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LIVE VACCINE; TUMOR NECROSIS FACTOR ALPHA; TYPHOID VACCINE; UNCLASSIFIED DRUG; VACTA; YELLOW FEVER VACCINE;

ADULT; ARTICLE; CONTROLLED STUDY; FEVER; HUMAN; HUMAN EXPERIMENT; HYPOTHESIS; IMMUNOPATHOGENESIS; INFECTION PREVENTION; MALAISE; MYALGIA; NORMAL HUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; VACCINATION; YELLOW FEVER;

EID: 0031912009     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/517806     Document Type: Article

References (16)

1. Fekade D, Knox K, Melka A, Lallo DG, Coxon RE, Warrell DA. Prevention of Jarisch-Herxheimer reaction by treatment with antibodies against tumor necrosis factor-α. N Engl J Med 1996;335:311-5.
2. Eigler A, Sinha B, Hartmann G, Endres S. Taming TNF: strategies to restrain this proinflammatory cytokine. Immunol Today 1997;18:487-92.
3. Richardson RP, Rhyne CD, Fong Y, et al. Peripheral blood leukocyte kinetics following in vivo lipopolysaccharide (LPS) administration to normal human subjects. Influence of elicited hormones and cytokines. Ann Surg 1989;210:239-45.
4. Cannon JG, Tompkins RG, Gelfand JA, et al. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis 1990;161:79-84.
5. Wheelock EF, Sibley WA. Circulating virus, interferon and antibody after vaccination with the 17-D strain of yellow fever virus. N Engl J Med 1965;273:194-8.
6. Krakauer T. Levels of interleukin-6 and tumor necrosis factor in serum from humans vaccinated with live, attenuated Francisella tularensis. Clin Diagn Lab Immunol 1995;2:487-8.
7. Petralli JK, Merigam TC, Wilbur JR. Circulating interferon after measles vaccination. N Engl J Med 1965;273:198-201.
8. Wallach D, Holtmann H, Engelmann H, Nophar Y. Sensitization and desensitization to lethal effects of tumor necrosis factor and IL-1. J Immunol 1988;140:2994-9.
9. Remick DG, Larrick J, Kunkel SL. Tumor necrosis factor-induced alterations in circulating leukocyte populations. Biochem Biophys Res Commun 1986;141:818-24.
10. van der Poll T, van Deventer SJ, Hack CE, et al. Effects on leukocytes after injection of tumor necrosis factor into healthy humans. Blood 1992;79:693-8.
11. Poltorak A, Peppel K, Beutler B. Receptor-mediated label-transfer assay (RELAY) - a novel method for the detection of plasma tumor necrosis factor at attomolar concentrations. J Immunol Methods 1994;169:93-9.
12. Willeaume V, Kruys V, Mijatovic T, Huez G. Tumor necrosis factor-α production induced by viruses and by lipopolysaccharides in macrophages: similarities and differences. J Inflamm 1996;46:1-12.
13. Valensi JP, Carlson JR, Van NG. Systemic cytokine profiles in BALB/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants. J Immunol 1994;153:4029-39.
14. Karttunen R, Surcel HM, Andersson G, Ekre HP, Herva E. Francisella tularensis-induced in vitro γ-interferon, tumor necrosis factor-α, and interleukin 2 responses appear within 2 weeks of tularemia vaccination in human beings. J Clin Microbiol 1991;29:753-6.
15. Ward BJ, Griffin DE. Changes in cytokine production after measles virus vaccination: predominant production of IL-4 suggests induction of a Th2 response. Clin Immunol Immunopathol 1993;67:171-7.
16. Gabay C, Smith FS, Eidlen D, Arend P. Interleukin 1 receptor antagonist (IL-1 Ra) is an acute-phase protein. J Clin Invest 1997;99:2930-40.